Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
|Articles|December 29, 2020
The Top 5 News and Updates in Mantle Cell Lymphoma That Patients May Have Missed in 2020
Author(s)CURE staff
A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.
Advertisement
There have been several updates in the field of mantle cell lymphoma (MCL) in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.
- Data from an analysis of approximately 1,200 patients with MCL collected across 12 treatment centers demonstrated that maintenance Rituxan (rituximab) was associated with improved progression-free survival and overall survival, but an autologous stem cell transplant was not.
READ MORE .
- In an interview, an expert from the John Theurer Cancer Center explained how a recent research boom in the treatment of MCL has improved outcomes.
READ MORE . - Velcade (bortezomib) not only delays the progression of MCL when given after stem cell transplant, but also prolongs survival. However, the treatment comes with significant side effects.
READ MORE . - Patients with MCL who were eligible for stem cell transplant saw a 97% overall response rate to a three-drug regimen, according to findings from two clinical trials.
READ MORE . - A treatment regimen with Gazyva (obinutuzumab) plus dexamethasone, high dose cytarabine and cisplatin was well tolerated in patients with MCL who were eligible for bone marrow transplantation, according to study results published in Lancet Haematology.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Advertisement
Advertisement
Trending on CURE
1
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
2
Top 5 Takeaways From ESMO 2026 That Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
4 Lung Cancer Results From ESMO 2026 Patients Should Know
5